Friday, May 28, 2010

Impact of Lipodystrophy on Quality of Life of People Living With HIV- Survey Results



1. How old are you?
 answered question1,325
 
skipped question
6
 Response
Percent
Response
Count
Under 15 years old
0.3%4
15-20
0.2%2
20-25
0.5%7
25-30
1.7%23
30-35
4.8%63
35-40
7.8%104
40-45
23.1%306
45-50
22.6%299
50-55
20.8%275
55-60
11.4%151
Over 60
6.9%91
DownloadCreate Chart2. What is your ethinicity?
 answered question1,325
 
skipped question
6
 Response
Percent
Response
Count
White
78.4%1,039
Black
7.7%102
Latino
9.1%121
Asian
1.7%22
American Indian
0.8%10
Other
2.3%31
DownloadCreate Chart3. What is your gender?
 answered question1,325
 
skipped question
6
 Response
Percent
Response
Count
Female
12.4%164
Male
87.2%1,155
Transgender
0.5%6
DownloadCreate Chart4. How long have you known that you are HIV positive?
 answered question1,325
 
skipped question
6
 Response
Percent
Response
Count
Under 5 years
10.1%134
5- 10 years
14.1%187
10-15 years
20.8%276
15-20 years
27.7%367
over 20 years
27.2%361
DownloadCreate Chart5. Are you currently taking HIV medications?
 answered question1,325
 
skipped question
6
 Response
Percent
Response
Count
Yes
94.9%1,258
No
5.1%67
DownloadCreate Chart6. If you are taking or have taken medications for HIV, how long have you taken them (total years)?
 answered question1,288
 
skipped question
43
 Response
Percent
Response
Count
Under 5 years
15.0%193
5-10 years
21.1%272
10-15 years
35.3%455
15-20 years
28.6%368
DownloadCreate Chart7. Have you taken any of these medications in the past?
 answered question1,170
 
skipped question
161
 Response
Percent
Response
Count
Zerit (D4T)
83.6%978
AZT
78.7%921
Crixivan
50.3%589
High dose Norvir
37.1%434
Hydroxyurea
11.2%131
DDI (videx)
55.0%644
DDC (Hivid)
29.4%344
DownloadCreate Chart8. Have you had body shape changes after starting HIV medications in the past?
 answered question1,331
 
skipped question
0
 Response
Percent
Response
Count
Yes
88.7%1,180
No
11.3%151
DownloadCreate Chart9. What kind of body changes are you experiencing or have you experienced?
 answered question1,296
 
skipped question
35
 Response
Percent
Response
Count
Involuntary weight loss/wasting
45.8%594
Abdominal (Belly) Fat Gain
61.9%802
Facial Wasting
79.9%1,035
Butt Wasting
70.3%911
Veiny Legs or Arms
68.5%888
Increased Breast Size
21.1%274
Buffalo Hump (Behind The Neck)
20.9%271
Increased Neck Size
16.4%213
Parotid Gland Enlargement (sides of face)
15.7%203
Other
6.4%83
Show repliesIf other, please specify106
DownloadCreate Chart10. Have you experienced depression or anxiety due to the body changes?
 answered question1,331
 
skipped question
0
 Response
Percent
Response
Count
Yes
88.4%1,177
No
11.6%154
DownloadCreate Chart11. Have you ever thought of killing yourself due to your body changes?
 answered question1,331
 
skipped question
0
 Response
Percent
Response
Count
Yes
26.3%350
No
73.7%981
DownloadCreate Chart12. Have you ever thought about not taking your HIV medications or have you ever stopped taking them because of fear of worsening your body changes?
 answered question1,331
 
skipped question
0
 Response
Percent
Response
Count
Yes
42.4%564
No
57.6%767
DownloadCreate Chart13. Have the body changes cause you to: (check all that apply)
 answered question1,256
 
skipped question
75
 Response
Percent
Response
Count
Stop socializing and going out to meet people
67.4%847
Stop dating
51.8%651
Decrease sexual activity
73.9%928
Increase sexual activity
3.9%49
Worry too much about people finding out you are HIV+
61.2%769
Be rejected by potential sexual partners
56.0%703
Affect your job performance
27.4%344
Stop looking at yourself in the mirror
58.0%729
Change your clothing style
56.0%703
Abuse drugs or alcohol to feel better
18.2%228
Deplete your finances in search of a solution
29.2%367
Other
6.7%84
Show repliesPlease Specify112
DownloadCreate Chart14. What have you done to try to reverse your body changes? (check all that apply)
 answered question1,242
 
skipped question
89
 Response
Percent
Response
Count
Exercised more
72.6%902
Watch what I eat
72.4%899
Got my face injected with a filler or cosmetic product
40.7%505
Got my parotid glands treated with radiation
1.4%18
Took supplements that I heard may help my body fat/muscle
43.0%534
Used testosterone
45.0%559
Used human growth hormone
17.1%212
Used nandrolone (Deca durabolin)
16.1%200
Used Oxandrin
13.8%171
Got liposuction
7.2%90
Got butt implants
1.7%21
Use padded underwear
13.3%165
Other
6.6%82
Show repliesIf other, please specify118
DownloadCreate Chart15. Have your insurance, ADAP/Ryan White clinic, HMO, health care system (for countries outside the US) and/or supplier patient assistance program paid for ANY of the solution(s) mentioned in the answer(s) in the previous question? (Check all that apply)
 answered question1,124
 
skipped question
207
 Response
Percent
Response
Count
No one has. I had to pay with my own money
63.2%710
Yes, my insurance company has
17.7%199
Yes, my HMO has
4.7%53
Yes, my ADAP/Ryan White program has
6.9%78
Yes, my country's health system has
7.9%89
Yes, a supplier's patient assistance program has
11.1%125
Show repliesPlease specify what was paid for279
DownloadCreate Chart16. Have you had facial wasting (lipoatrophy)?
 answered question1,330
 
skipped question
1
 Response
Percent
Response
Count
Yes
80.3%1,068
No
19.7%262
DownloadCreate Chart17. What option have you used to improve your facial lipoatrophy? (check all that apply)
 answered question1,144
 
skipped question
187
 Response
Percent
Response
Count
I have done nothing
41.3%472
I have used BioAlcamid
7.1%81
I have used silicone
6.8%78
I have used Sculptra (New Fill or polylactic acid)
29.6%339
I have used Radiesse
5.2%60
I have used PMMA in Rio, Tijuana or other
4.4%50
I have switched off from Zerit to Viread, Ziagen, Epzicom or Truvada
31.0%355
I have switched off from AZT to Viread, Ziagen, Epzicom, or Truvada
12.3%141
I have taken Uridine (Nucleomaxx)
1.1%13
Other
8.4%96
Show repliesplease specify157
PAGE: PAGE 2
DownloadCreate Chart18. Do you have or have you had high cholesterol/triglycerides?
 answered question1,297
 
skipped question
34
 Response
Percent
Response
Count
Yes
65.8%853
No
28.0%363
I do not know
6.2%81
DownloadCreate Chart19. Have you had or do you have higher than normal blood glucose (sugar)?
 answered question1,297
 
skipped question
34
 Response
Percent
Response
Count
Yes
27.4%356
No
58.7%761
I do not know
13.9%180
DownloadCreate Chart20. Have you heard from your doctor or other sources that belly fat, high LDL (bad) cholesterol, high triglycerides or high blood sugar may affect your health and mortality?
 answered question1,297
 
skipped question
34
 Response
Percent
Response
Count
Yes
75.5%979
No
19.8%257
I do not remember
4.7%61
DownloadCreate Chart21. Do you think some HIV medications can increase belly fat?
 answered question1,296
 
skipped question
35
 Response
Percent
Response
Count
Yes
81.8%1,060
No
0.6%8
Not sure
15.6%202
I think HIV causes it, not the medications
2.0%26
DownloadCreate Chart22. Do you think some HIV medications can increase fat loss under the skin (facial wasting, veiny legs/arms, fat loss in the butt)?
 answered question1,296
 
skipped question
35
 Response
Percent
Response
Count
Yes
88.8%1,151
No
0.8%11
Not sure
6.9%89
I think HIV causes it, not the medications
3.5%45
Download23. What do you want me to tell or ask lipodystrophy researchers about what the research needs are for that problem?
 answered question690
 
skipped question
641
 Response
Count
Show replies690

FDA Committee Unanimously Recommends Egrifta for Lipodystrophy


FROM POZ.COM


May 27, 2010
FDA Committee Unanimously Recommends Egrifta for Lipodystrophy


A U.S. Food and Drug Administration (FDA) advisory committee has unanimously recommended that Egrifta (tesamorelin), Montreal-based Theratechnologies' experimental product for the treatment of excess abdominal fat in HIV-positive people with lipodystrophy, be approved by the agency.  Though the FDA is not required to follow the recommendations of its advisory committees, it usually does so.

Several of the 16 panelists making up the Endocrinologic and Metabolic Drugs Advisory Committee, which met May 27 at the University of Maryland University College (UMUC) Marriott Conference Centers in Adelphi, Maryland, stressed that there is a need for additional follow-up studies to monitor the long-term safety and efficacy of the drug.

Egrifta is a synthetic human growth hormone-releasing factor. Phase III clinical trials of the drug indicate that it decreases visceral adipose tissue (VAT)—fat deep within the belly—by about 17 percent.

According to Christian Marsolais, MD, vice president of clinical research and medical affairs at Theratechnologies, who reviewed the Phase III efficacy results at today's hearing, 57.4 percent of patients taking Egrifta experienced an 8 percent or greater reduction in VAT—the primary goals of the studies—compared with 29.3 percent of the placebo group.

Unlike Serostim (recombinant human growth hormone), an earlier contender for treating excess VAT, Egrifta has long been suggested to have fewer side effects when used for at least a year, including a minimal effect on blood sugar (glucose) levels.

There were, however, conflicting reports at today's hearing regarding the risk of diabetes in people receiving Egrifta in the Phase III clinical trials.

Graziella Soulban, MD, director of clinical research at Theratechnologies, reported higher rates of pre-diabetes and diabetes among those receiving Egrifta, compared with placebo, during the first 26 weeks of the studies. But between weeks 26 and 52 of the studies, however, the number of people with glucose intolerance and diabetes dropped. 

Ali Mohamadi, MD, a clinical reviewer from the FDA, unveiled a slightly more detailed analysis. According to the FDA safety analysis reported this morning, 49.2 percent of patients receiving Egrifta had no instances of raised blood-glucose levels. However, 17.3 percent of those receiving Egfrifta had three or more increased blood-glucose measurements during the clinical trial, compared with 7.3 percent of those receiving placebo.

Mohamadi also reported that 25 percent of patients in the tesamorelin group who started off as pre-diabetic eventually went on to develop frank diabetes in the studies. Among those who began treatment without a history of diabetes and had normal glucose levels, Mohamadi confirmed, the risk of diabetes during the study remains low.

Increases in insulin-like growth factor 1, or IGF-1, was another safety issue discussed at length during today's meeting. Though increases in IGF-1 are considered to be an indicator of Egrifta's activity, IGF-1 has also been suggested to promote tumor growth, which can be problematic in a population of individuals—including people living with HIV—who already face a higher risk of cancer. According to Mohamadi, a third of patients receiving Egrifta had significantly elevated IGF-1 levels. However, according to Soulban, these increases were not found to be associated with an increased risk of any type of cancer in the 52-week Phase III studies.

Mohamadi reiterated that decreases in decreases in VAT associated with the use of Egrifta have not been shown to decrease the risk of cardiovascular disease—an important potential benefit of any drug that treats abdominal obesity—and several panelists reiterated that future studies should explore this goal. And though the panelists were divided on the data submitted to the FDA regarding improvements in body image and body perception in the studies, many were clearly impressed by the mid-day public testimony offered by three people living with HIV—Jeff Berry of the AIDS Treatment Activists Coalition and two Egrifta clinical trial participants—who emphasized the detrimental effects of lipodystrophy in people living with HIV.

As the clock approached 4 p.m., the final vote was cast by the advisory committee members, in response to a single question put forth by the FDA: Does the risk-benefit assessment support approval of Egrifta? Sixteen voted "yes"—there were zero "no" votes and no abstentions.

Several panelists stressed that follow-up data should be collected to better understand the long-term risks of glucose abnormalities and IGF-1 increases. Theratechnologies noted that it is already planning a safety monitoring program that will go into effect if the FDA agrees with the advisory committee panel and approves the drug for use in the United States.

A final decision from the FDA is expected within the next two months. The agency has until July 27 to notify Theratechnologies of the drug's approval status and of any post-marketing studies that must be conducted.

Support PoWeR

Program For Wellness Restoration

Health News

Blog Archive

The Cure of HIV is Possible in Our Lifetime